Kinfo
Avalo Therapeutics Inc. logo

Avalo Therapeutics Inc.

AVTXNASDAQHealthcare·US · USD
$19.45
-0.10 (-0.51%)
Prices as of August 13, 2026 · market closed

Price

Key statistics

Valuation
Market cap1.04B USD
Enterprise value644.14M USD
Trailing P/E2.30
Forward P/E-7.43
PEG ratio-0.04
Price / sales17,770.61
Price / book2.31
Profitability
Gross margin0.00%
Operating margin-154847.45%
Profit margin100.00%
Return on assets-18.50%
Return on equity-36.27%
Income (TTM)
Revenue59.00K USD
Gross profit-47.89M USD
EBITDA-91.25M USD
Net income-100.33M USD
Diluted EPS-$4.41
Rev. growth (YoY)0.00%
Balance sheet
Total cash400.28M USD
Total debt242.00K USD
Debt / equity0.05
Current ratio19.31
Book value / share$8.48
Cash flow (TTM)
Operating cash flow-68.29M USD
Levered free cash flow-23.27M USD
Shares & price
Shares outstanding52.90M
Float43.74M
Held by institutions91.66%
Beta0.79
50-day MA$17.38
200-day MA$16.64
52-week high$24.27
52-week low$8.41
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-06-0.62-0.83−33.87%2026-05-13-1.03-0.98+4.85%2026-03-23-1.49-0.37+75.17%2026-03-02-0.54-0.70−29.63%
About Avalo Therapeutics Inc.

Avalo Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases with significant unmet needs. The company targets the IL-1β pathway, a central driver of inflammation, through its lead asset, abdakibart (AVTX-009), a humanized monoclonal antibody currently in a Phase 2 LOTUS trial for hidradenitis suppurativa, a chronic inflammatory skin condition. Avalo Therapeutics Inc. is exploring the potential of AVTX-009 in additional immune-mediated indications to address broader patient populations. Founded in 2011 and headquartered in Wayne, Pennsylvania, the company focuses on advancing novel therapeutics driven by scientific innovation and compassion for those affected by chronic inflammatory conditions. Its pipeline emphasizes best-in-class medicines to transform lives in areas lacking effective therapies, operating within the health technology sector to develop and potentially commercialize targeted biologics for immune dysregulation.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Garry A. Neil M.D.
Employees
23
Headquarters
Rockville, MD, United States

Frequently asked questions about Avalo Therapeutics Inc.